Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu
Enjoy your FREE PREVIEW which shows only 2020 data and 25 documents. For full access, try it free at any time.        

Cannabis: Compositions

Search All Patents in Cannabis: Compositions


Patent US10603288


Issued 2020-03-31

Use Of Cannabinoids In The Treatment Of Epilepsy

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).


Classification


Slightly Less than Average Length Specification


View the Patent Matrix® Diagram to Explore the Claim Relationships

USPTO Full Text Publication >

4 Independent Claims

  • Independent Claim 1. A method of treating seizures in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol(CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments.

  • Independent Claim 13. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w)CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day.

  • Independent Claim 14. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD,wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day.

  • Independent Claim 16. A method of treating seizures in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD isadministered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments.